CN115006592A - 一种脱细胞真皮复合材料、制备方法及用途 - Google Patents
一种脱细胞真皮复合材料、制备方法及用途 Download PDFInfo
- Publication number
- CN115006592A CN115006592A CN202210681761.2A CN202210681761A CN115006592A CN 115006592 A CN115006592 A CN 115006592A CN 202210681761 A CN202210681761 A CN 202210681761A CN 115006592 A CN115006592 A CN 115006592A
- Authority
- CN
- China
- Prior art keywords
- dermis
- acellular
- composite material
- placenta tissue
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002131 composite material Substances 0.000 title claims abstract description 31
- 230000002500 effect on skin Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 210000004207 dermis Anatomy 0.000 claims abstract description 40
- 210000005059 placental tissue Anatomy 0.000 claims abstract description 30
- 210000000683 abdominal cavity Anatomy 0.000 claims abstract description 28
- 239000002002 slurry Substances 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 19
- 238000002791 soaking Methods 0.000 claims abstract description 11
- 230000001954 sterilising effect Effects 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 6
- 238000009777 vacuum freeze-drying Methods 0.000 claims abstract description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 229920002126 Acrylic acid copolymer Polymers 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 235000010410 calcium alginate Nutrition 0.000 claims description 3
- 239000000648 calcium alginate Substances 0.000 claims description 3
- 229960002681 calcium alginate Drugs 0.000 claims description 3
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 3
- 229940045110 chitosan Drugs 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 229960004667 ethyl cellulose Drugs 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229940014259 gelatin Drugs 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 2
- 238000002203 pretreatment Methods 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 24
- 210000004027 cell Anatomy 0.000 abstract description 18
- 206010016717 Fistula Diseases 0.000 abstract description 5
- 230000003890 fistula Effects 0.000 abstract description 5
- 239000011159 matrix material Substances 0.000 abstract description 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 abstract description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 abstract description 3
- 102000016943 Muramidase Human genes 0.000 abstract description 3
- 108010014251 Muramidase Proteins 0.000 abstract description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 abstract description 3
- 230000000840 anti-viral effect Effects 0.000 abstract description 3
- 239000004325 lysozyme Substances 0.000 abstract description 3
- 229960000274 lysozyme Drugs 0.000 abstract description 3
- 235000010335 lysozyme Nutrition 0.000 abstract description 3
- 239000002245 particle Substances 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000002313 adhesive film Substances 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000006261 foam material Substances 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 210000001691 amnion Anatomy 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000001136 chorion Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008383 multiple organ dysfunction Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010056519 Abdominal infection Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101000690940 Homo sapiens Pro-adrenomedullin Proteins 0.000 description 1
- 208000008081 Intestinal Fistula Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 102000046663 human ADM Human genes 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/362—Skin, e.g. dermal papillae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种脱细胞真皮复合材料的制备方法，包括：一种脱细胞真皮复合材料的制备方法，包括：步骤1，将真皮原料制备成脱细胞真皮；步骤2，制备胎盘组织浆料；步骤3，将所述脱细胞真皮浸渍于所述胎盘组织浆料中，经真空冷冻干燥和灭菌后，获得脱细胞真皮复合材料。本发明经过特殊处理的脱细胞真皮基质(ADM)复合材料含有胎盘组织浆料颗粒，含有多种溶菌酶和抗体，具有抗病毒和杀菌作用，含有碱性成纤维生长因子等多种细胞因子，有着良好的生物相容性，其覆盖在腹腔开放的肠管上方，避免与肠管的过度粘连进一步损伤肠管，促进肠浆膜层修复，从而减少空气瘘的发生。
Description
技术领域
本发明涉及医用材料领域，具体涉及一种脱细胞真皮复合材料、制备方法及用途。
背景技术
腹部严重创伤、复杂肠瘘等均可导致腹腔高压、腹腔感染灶引流困难或术后无法关腹，特殊情况下需要行腹腔开放(OA)疗法。腹腔开放可降低腹腔内压力、防止腹腔间隙综合征(ACS)、防治多器官功能障碍(MODF)，还便于感染坏死组织反复清除、通畅引流。但由于腹腔开放疗法丧失了对腹腔内脏器的保护作用，肠道、肝脏等腹腔内脏器直接暴露于各种敷料或空气中，不可避免地造成了大量体液及蛋白质的丢失、肠壁损伤出血、肠功能障碍等诸多并发症。其中，肠空气瘘无疑是最严重的。因此，在腹腔开放后早期行暂时性关腹(TAC)就尤为重要，TAC可以容纳和保护腹内脏器，避免污染，防止肠管脱出、干燥、水肿、粘连和损伤，减少体液丢失，便于再进腹，保护切口边缘避免其回缩，维持腹腔容积，为确定性腹腔关闭创造条件。因此腹腔开放疗法的关键技术在于能够采用特定的腹腔开放临时关闭保护材料及辅助装置进行安全有效的腹腔临时关闭。
TAC包括多种不同类型，其中负压辅助关腹法(VSD)是较为常用的一种类型；它主要由医用泡沫材料、黏性贴膜和负压管路系统构成。将医用泡沫材料放置于医用敷料(如凡士林纱布)覆盖的肠管上方，用黏性贴膜覆盖封闭，剪去一小片黏性贴膜并将一个接有负压管路系统的接口垫置于该缺损处。负压可使医用泡沫敷料(如聚氨酯海绵层)塌陷，从而对腹膜和筋膜施加一个向内侧的牵引力，同时可以将腹腔内的液体引流至体外。但是，由于敷料材料的限制，目前仍大量使用凡士林纱布覆盖在肠管上方，然后盖上聚氨酯海绵层接负压吸引，一方面生物相容性差，肠管易损伤面临着发生肠空气瘘的风险，另一方面，通透性不佳，引流效果受限。因此，寻求生物相容性好、通透性佳的生物材料迫在眉睫。
发明内容
本发明的目的是提供一种生物相容性好、通透性佳的生物材料。
为了达到上述目的，本发明提供了一种脱细胞真皮复合材料的制备方法，包括：
一种脱细胞真皮复合材料的制备方法，包括：
步骤1，将真皮原料制备成脱细胞真皮；
步骤2，制备胎盘组织浆料；
步骤3，将所述脱细胞真皮浸渍于所述胎盘组织浆料中，经真空冷冻干燥和灭菌后，获得脱细胞真皮复合材料。
可选地，步骤2包括：
步骤2.1，对胎盘组织预处理；
步骤2.2，向预处理后的胎盘组织添加含有抗菌剂的有机缓释介质，获得所述胎盘组织浆料；所述抗菌剂为纳米银、纳米氧化锌、纳米铜、抗菌多肽、抗菌素中的一种或多种；所述有机缓释介质为丙烯酸类共聚物、聚乙烯醇与聚乙二醇共聚物、聚山梨酯80、丙三醇、乙基纤维素、壳聚糖、海藻酸钙、海藻酸钠、明胶中的一种或多种。
可选地，步骤2.1的预处理包括：去除血污、细胞、DNA后，消毒、干燥和颗粒化处理。
可选地，还包括对所述脱细胞真皮的原料进行打孔处理的步骤，孔径为1mm-2mm，孔距为2mm-3mm。
可选地，还包括对所述脱细胞真皮进行等离子体表面改性的步骤。
可选地，还包括对所述脱细胞真皮的原料进行切片的步骤，切片后的厚度为0.12mm-0.5mm。
可选地，步骤3中浸渍时间为20h-30h。
可选地，所述脱细胞真皮的原料为同种或异种真皮。
本发明还提供了一种通过上述制备方法制备的脱细胞真皮复合材料。
本发明还提供了一种通过上述制备方法制备的脱细胞真皮复合材料的用途，所述脱细胞真皮复合材料用于腹腔开放暂时性关腹。
本发明的有益效果为：本发明经过特殊处理的脱细胞真皮基质(ADM)复合材料含有胎盘组织浆料颗粒，含有多种溶菌酶和抗体，具有抗病毒和杀菌作用，含有碱性成纤维生长因子等多种细胞因子，有着良好的生物相容性，其覆盖在腹腔开放的肠管上方，避免与肠管的过度粘连进一步损伤肠管，促进肠浆膜层修复，从而减少空气瘘的发生。优化的，可以添加含有抗菌剂的有机缓释介质，进一步增强效果。采用的脱细胞真皮基质(ADM)复合材料进行了超薄切片、打孔，同时胎盘组织浆料颗粒化处理，也有利于充分引流及降低成本。
具体实施方式
下面将对本发明的技术方案进行清楚、完整地描述，显然，所描述的实施例是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
本发明提供了一种脱细胞真皮复合材料的制备方法，包括：
1.将真皮原料制备成脱细胞真皮
步骤1.1，对真皮原料进行切片，切片后的厚度为0.12mm-0.5mm。可选地，真皮原料来源于同种或异种真皮。
步骤1.2，对真皮脱细胞处理，获得脱细胞真皮。
步骤1.3，对脱细胞真皮进行打孔处理，孔径为1mm-2mm，孔距为2mm-3mm。
步骤1.4，对脱细胞真皮进行等离子体表面改性。
2.制备胎盘组织浆料
步骤2.1，对胎盘组织预处理，包括：去除血污、细胞、DNA后，消毒、干燥和颗粒化处理。
步骤2.2，向预处理后的胎盘组织添加含有抗菌剂的有机缓释介质，获得所述胎盘组织浆料；所述抗菌剂为纳米银、纳米氧化锌、纳米铜、抗菌多肽、抗菌素中的一种或多种；所述有机缓释介质为丙烯酸类共聚物、聚乙烯醇与聚乙二醇共聚物、聚山梨酯80、丙三醇、乙基纤维素、壳聚糖、海藻酸钙、海藻酸钠、明胶中的一种或多种。
3.将所述脱细胞真皮浸渍于所述胎盘组织浆料中，浸渍时间为20h-30h，之后经真空冷冻干燥和灭菌后，获得脱细胞真皮复合材料。
实施例1
步骤1，制备脱细胞真皮。
清洗成熟大白猪(约克夏猪种)猪背部皮，去毛刀去毛后，以取皮鼓切取厚度为0.25毫米厚的皮片抛弃，除去表皮，毛发及毛囊，再用取皮鼓取厚度为0.25毫米厚真皮片备用(常规ADM的1/2厚度)。加入质量分数为0.5％的过氧乙酸消毒液里浸泡40分钟。使用磷酸盐缓冲盐水清洗3次，每次均在摇床上摇30分钟。加入脱细胞液，将猪真皮片与脱细胞液充分混合以及反应，在摇床上混合10小时，脱细胞液为4-羟乙基哌嗪乙磺酸缓冲液，其pH值为8，每升4-羟乙基哌嗪乙磺酸缓冲液含20毫摩尔4-羟乙基哌嗪乙磺酸，脱细胞液中含有脱氧胆酸钠，脱氧胆酸钠的质量体积百分比溶度为2％，脱细胞液的体积与猪真皮片体积之比为30：1。吸出脱细胞液，然后加入磷酸盐缓冲盐水充分清洗猪真皮片，使用磷酸盐缓冲盐水清洗3次，每次均在摇床上摇30分钟，得到ADM。然后，行打孔处理，打孔孔径为1.5mm，孔距为2mm，最后采用低温等离子体技术改性。
步骤2，制备胎盘组织浆料。
将获取的胎盘组织在无菌条件下送至控制处理环境，并浸泡在盛有2.0wt％氯化钠水溶液的无菌盆中进行润洗，对羊膜和绒毛膜组织进行处理，去除血污、细胞和DNA，并对去细胞的组织进行消毒：首先，用2.0wt％氯化钠水溶液反复清洗以去除血污；然后，将除去血污的组织浸泡在3.0wt％氯化钠水溶液中，在室温下摇动混合120分钟以去除细胞；之后，将去除细胞的组织放入去DNA溶液(由HEPES溶液、MgCl2溶液、CaCl2溶液、纯化水、DNA酶混合组成)中，在室温下摇动混合5小时至组织中残留DNA含量满足不大于250纳克/每毫克组织；最后，将去DNA的组织浸泡在70％异丙醇中浸泡50分钟进行消毒。然后将模具放入烘箱中，在40℃温度条件下干燥60分钟，得到干燥组织；采用低温下超声匀浆技术或者冻融破碎法，颗粒化处理。然后添加含有抗菌剂的有机缓释介质成为胎盘组织浆料，有机缓释介质选用聚乙烯醇与聚乙二醇共聚物、壳聚糖；抗菌剂为纳米银。
步骤3，将获得的多孔脱细胞真皮浸渍于胎盘组织浆料中24h，经真空冷冻干燥和灭菌后，获得脱细胞真皮复合材料。
本实施例制备的脱细胞真皮复合材料的使用方法为：将脱细胞真皮复合材料裁剪成较腹腔开放区域稍小的面积，覆盖在腹腔开放的肠管上方，接着放置医用泡沫材料(如聚氨酯海绵层)成相近大小，用黏性贴膜覆盖封闭，剪去一小片黏性贴膜并将一个接有负压管路系统的接口垫置于该缺损处。负压可使医用泡沫敷料塌陷，从而对腹腔施加一个向内侧的牵引力，同时可以将腹腔内的液体引流至体外。
实施例2
步骤1，制备脱细胞真皮。
取商品人源ADM，行超薄切片处理，厚度为原来ADM的1/2，约0.25mm。然后行打孔处理，孔径为1.5mm，孔距为2mm，最后采用低温等离子体技术改性。
步骤2，制备胎盘组织浆料。
将获取的胎盘组织在无菌条件下送至控制处理环境，并浸泡在盛有2.0wt％氯化钠水溶液的无菌盆中进行润洗，对羊膜和绒毛膜组织进行处理，去除血污、细胞和DNA，并对去细胞的组织进行消毒：首先，用2.0wt％氯化钠水溶液反复清洗以去除血污；然后，将除去血污的组织浸泡在3.0wt％氯化钠水溶液中，在室温下摇动混合120分钟以去除细胞；之后，将去除细胞的组织放入去DNA溶液(由HEPES溶液、MgCl2溶液、CaCl2溶液、纯化水、DNA酶混合组成)中，在室温下摇动混合5小时至组织中残留DNA含量满足不大于250ng/每mg组织；最后，将去DNA的组织浸泡在70％异丙醇中浸泡50分钟进行消毒。然后将模具放入烘箱中，在40℃温度条件下干燥60分钟，得到干燥组织；采用低温下超声匀浆技术或者冻融破碎法，颗粒化处理。然后添加含有抗菌剂的有机缓释介质成为胎盘组织浆料，有机缓释介质选用聚乙烯醇与聚乙二醇共聚物、壳聚糖；抗菌剂为抗菌多肽。
步骤3，将获得的多孔脱细胞真皮浸渍于胎盘组织浆料中24h，经真空冷冻干燥和灭菌后，获得脱细胞真皮复合材料。
本实施例制备的脱细胞真皮复合材料的使用方法为：经腹腔开放区域周围腹壁留置并固定1-2根乳胶引流管或双套管至腹腔，将特殊处理的ADM复合材料裁剪成较腹腔开放区域稍小的面积，覆盖在腹腔开放的肠管上方，接着放置医用泡沫材料(如聚氨酯海绵层)成相近大小，用黏性贴膜覆盖封闭，剪去一小片黏性贴膜并将一个接有负压管路系统的接口垫置于该缺损处。负压可使医用泡沫敷料塌陷，从而对腹腔施加一个向内侧的牵引力，同时可以将腹腔内的液体引流至体外。同时可以经双套管持续冲洗渗出的肠内容物。
综上所述，本发明经过特殊处理的脱细胞真皮基质(ADM)复合材料含有胎盘组织浆料颗粒，含有多种溶菌酶和抗体，具有抗病毒和杀菌作用，含有碱性成纤维生长因子等多种细胞因子，有着良好的生物相容性，其覆盖在腹腔开放的肠管上方，避免与肠管的过度粘连进一步损伤肠管，促进肠浆膜层修复，从而减少空气瘘的发生。优化的，可以添加含有抗菌剂的有机缓释介质，进一步增强效果。采用的脱细胞真皮基质(ADM)复合材料进行了超薄切片、打孔，同时胎盘组织浆料颗粒化处理，也有利于充分引流及降低成本。
尽管本发明的内容已经通过上述优选实施例作了详细介绍，但应当认识到上述的描述不应被认为是对本发明的限制。在本领域技术人员阅读了上述内容后，对于本发明的多种修改和替代都将是显而易见的。因此，本发明的保护范围应由所附的权利要求来限定。
Claims (10)
1.一种脱细胞真皮复合材料的制备方法，其特征在于，包括：
步骤1，将真皮原料制备成脱细胞真皮；
步骤2，制备胎盘组织浆料；
步骤3，将所述脱细胞真皮浸渍于所述胎盘组织浆料中，经真空冷冻干燥和灭菌后，获得脱细胞真皮复合材料。
2.如权利要求1所述的制备方法，其特征在于，步骤2包括：
步骤2.1，对胎盘组织预处理；
步骤2.2，向预处理后的胎盘组织添加含有抗菌剂的有机缓释介质，获得所述胎盘组织浆料；所述抗菌剂为纳米银、纳米氧化锌、纳米铜、抗菌多肽、抗菌素中的一种或多种；所述有机缓释介质为丙烯酸类共聚物、聚乙烯醇与聚乙二醇共聚物、聚山梨酯80、丙三醇、乙基纤维素、壳聚糖、海藻酸钙、海藻酸钠、明胶中的一种或多种。
3.如权利要求1所述的制备方法，其特征在于，步骤2.1的预处理包括：去除血污、细胞、DNA后，消毒、干燥和颗粒化处理。
4.如权利要求1所述的制备方法，其特征在于，还包括对所述脱细胞真皮的原料进行打孔处理的步骤，孔径为1mm-2mm，孔距为2mm-3mm。
5.如权利要求1所述的制备方法，其特征在于，还包括对所述脱细胞真皮进行等离子体表面改性的步骤。
6.如权利要求1所述的制备方法，其特征在于，还包括对所述脱细胞真皮的原料进行切片的步骤，切片后的厚度为0.12mm-0.5mm。
7.如权利要求1所述的制备方法，其特征在于，步骤3中浸渍时间为20h-30h。
8.如权利要求1所述的制备方法，其特征在于，所述脱细胞真皮的原料为同种或异种真皮。
9.一种通过权利要求1-8任意一项所述的制备方法制备的脱细胞真皮复合材料。
10.一种通过权利要求1-8任意一项所述的制备方法制备的脱细胞真皮复合材料的用途，其特征在于，所述脱细胞真皮复合材料用于腹腔开放暂时性关腹。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210681761.2A CN115006592B (zh) | 2022-06-15 | 2022-06-15 | 一种脱细胞真皮复合材料、制备方法及用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210681761.2A CN115006592B (zh) | 2022-06-15 | 2022-06-15 | 一种脱细胞真皮复合材料、制备方法及用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115006592A true CN115006592A (zh) | 2022-09-06 |
| CN115006592B CN115006592B (zh) | 2024-01-30 |
Family
ID=83074602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210681761.2A Active CN115006592B (zh) | 2022-06-15 | 2022-06-15 | 一种脱细胞真皮复合材料、制备方法及用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115006592B (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2205446A1 (en) * | 1994-11-22 | 1996-05-30 | Tei Biosciences Inc. | Biopolymer foams having extracellular matrix particulates |
| US20080027542A1 (en) * | 2006-05-09 | 2008-01-31 | Lifecell Corporation | Reinforced Biological Tissue |
| CN102580153A (zh) * | 2012-03-09 | 2012-07-18 | 潘银根 | 一种制备脱细胞真皮基质医用组织补片的方法 |
| CN103415308A (zh) * | 2011-01-14 | 2013-11-27 | 图托根医疗有限责任公司 | 使用硫化钠溶液由动物真皮制造移植物 |
| CN104822342A (zh) * | 2012-10-08 | 2015-08-05 | 矩阵心血管疾病有限公司 | 用于治疗生物组织的方法和系统 |
| CN110975010A (zh) * | 2019-11-25 | 2020-04-10 | 银丰低温医学科技有限公司 | 一种胎盘组织基质材料及其制备方法 |
| CN113274552A (zh) * | 2021-05-21 | 2021-08-20 | 浙江德普斯医疗科技股份有限公司 | 缓释抗菌型脱细胞基质生物材料及其制备方法 |
-
2022
- 2022-06-15 CN CN202210681761.2A patent/CN115006592B/zh active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2205446A1 (en) * | 1994-11-22 | 1996-05-30 | Tei Biosciences Inc. | Biopolymer foams having extracellular matrix particulates |
| US20080027542A1 (en) * | 2006-05-09 | 2008-01-31 | Lifecell Corporation | Reinforced Biological Tissue |
| CN103415308A (zh) * | 2011-01-14 | 2013-11-27 | 图托根医疗有限责任公司 | 使用硫化钠溶液由动物真皮制造移植物 |
| CN102580153A (zh) * | 2012-03-09 | 2012-07-18 | 潘银根 | 一种制备脱细胞真皮基质医用组织补片的方法 |
| CN104822342A (zh) * | 2012-10-08 | 2015-08-05 | 矩阵心血管疾病有限公司 | 用于治疗生物组织的方法和系统 |
| CN110975010A (zh) * | 2019-11-25 | 2020-04-10 | 银丰低温医学科技有限公司 | 一种胎盘组织基质材料及其制备方法 |
| CN113274552A (zh) * | 2021-05-21 | 2021-08-20 | 浙江德普斯医疗科技股份有限公司 | 缓释抗菌型脱细胞基质生物材料及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 仲剑平等, 第二军医大学出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115006592B (zh) | 2024-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peng et al. | Recent progress of collagen, chitosan, alginate and other hydrogels in skin repair and wound dressing applications | |
| CA1234653A (en) | Biomaterial | |
| CA1213521A (en) | Hydrophilic biopolymeric copolyelectrolytes, and biodegradable dressings comprising same | |
| WO2000033894A1 (en) | Collagen hemostatic foam | |
| CN101773687B (zh) | 一种复合软组织补片的制备方法 | |
| CN100540065C (zh) | 辐照交联多孔网状脱细胞羊膜水凝胶敷料的制作方法 | |
| JPH10113384A (ja) | 医用代替膜及びその製造方法 | |
| EP1487506B1 (en) | Preparation for wound healing and prevention of bandage adhesion to the wound | |
| CN203389201U (zh) | 一种伤口创面负压包扎装置 | |
| CN115006592B (zh) | 一种脱细胞真皮复合材料、制备方法及用途 | |
| WO1998053850A2 (en) | Compositions and means for the treatment of burns and other cutaneous traumas | |
| WULLSTEIN | Tympanoplasty: The Problem of the Free Graft and the Mucous Membrane Graft | |
| Laurian et al. | Amniotic graft in the management of severe epistaxis due to hereditary haemorrhagic telangiectasia | |
| CN112641993B (zh) | 牙窝止血填充材料 | |
| CN112516175B (zh) | 海螵蛸的处理方法、海螵蛸产品及止血促愈合材料 | |
| CN114984323B (zh) | 一种腹壁缺损修复材料及制备方法 | |
| CN111671976A (zh) | 抗菌胶原膜及其制备方法 | |
| CN112569407B (zh) | 一种胎盘组织工程去免疫原皮肤支架及其制备方法 | |
| LIU et al. | THE USE OF DEHYDRATED AMNIOTIC GRAFT AFTERRADICAL MASTOIDECTOMY | |
| Chanda et al. | Use of glutaraldehyde-gentamicin-treated bovine pericardium as a wound dressing | |
| CN110893250B (zh) | 瘢痕/粘连阻挡膜及其制备方法和用途 | |
| CN116196459A (zh) | 一种组织修复止血膜及其制备方法和应用 | |
| US20030072750A1 (en) | Compositions and means for the treatment of burns and other cutaneous traumas | |
| RU2386436C1 (ru) | Способ лечения обширных ран | |
| Chong et al. | Skin sparing saucerisation: Case report of a novel carbuncle excision technique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |